Similar Levels Of HIV-Dna And Residual Viremia Are Found In Virologically Suppressed Individuals Who Continue A Two-Drug Regimen With Dolutegravir Plus One Reverse Transcriptase Inhibitor Or Switch To Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafen

European Meeting on HIV & Hepatitis 2020

Case Report: Poor Adherence To Dolutegravir Is Associated With Selection Of Resistance Mutations T66I, G118R, E138A And L74I

European Meeting on HIV & Hepatitis 2020

Multicentric Castleman Disease HHV-8 Related In A HIV Patient

European Meeting on HIV & Hepatitis 2020

HIV Seronegativity After Rapid Art: A Case Demonstrating Future Challenges In HIV Confirmation Testing In The Era Of iART

European Meeting on HIV & Hepatitis 2020

Variability In HIV Proviral DNA Genotyping Results From A Single Blood Draw

European Meeting on HIV & Hepatitis 2020

Virological Efficacy And Resistance Evaluation In People Living With HIV Starting An STR Regimen

European Meeting on HIV & Hepatitis 2020

Resistant Minority Variants Observed In Failing Patients At Week 48 In Anrs 170 Quatuor Trial (A 4/7 Days Maintenance Strategy Vs A 7/7 Days Regimen In Patients With Controlled Viral Load)

European Meeting on HIV & Hepatitis 2020

Molecular Characterization In Hcv Late Relapser Patients Treated With Direct-Acting Antiviral (DAA) Drugs

European Meeting on HIV & Hepatitis 2020

Clinical And Virological Characteristics And Retreatment Of Patients With Chronic Hepatitis C Virus Infection And Failure To Sofosbuvir, Velapatasvir, And Voxilaprevir In Real-World

European Meeting on HIV & Hepatitis 2020

Pharmaco-Virological Algorithm To Target Risk Of Resistance Among A Population Of HIV-Infected Female Sex Workers In Togo

European Meeting on HIV & Hepatitis 2020

Impact Of Sexually Transmitted Infections On Seminal HIV Levels Among Undetectable Patients

European Meeting on HIV & Hepatitis 2020

The Burden Of Serious Non-AIDS-Defining Events Among Admitted cART-Naive HIV/AIDS Patients In China: An Observational Cohort Study

European Meeting on HIV & Hepatitis 2020

Bone Mineral Density In Patients With HIV Infection And Chronic Hepatitis C

European Meeting on HIV & Hepatitis 2020

The Prevalence Of Hepatitis B Virus Seromarkers In Patients With HIV/Hcv Coinfection. An Egyptian Cross-Sectional Study

European Meeting on HIV & Hepatitis 2020

Seroprevalence And Co-Infections HIV, HBV And HCV Among Clinic Attenders At Laquintinie Hospital In Douala, Cameroon

European Meeting on HIV & Hepatitis 2020

Using Next-Generation Sequencing To Understand The Phylogenetics And Networks Of Generalised HIV Epidemics In Africa

European Meeting on HIV & Hepatitis 2020

The Efficacy Of First-Line Therapy Based On Rpv In HIV-Infected Patients With Pre-Existing E138A Mutation In Reverse Transcriptase

European Meeting on HIV & Hepatitis 2020

Number, Type And Cost Of Microbiological Assays During HIV Pre-Exposure Prophylaxis: The Experience Of A French Hospital

European Meeting on HIV & Hepatitis 2020

Long-Acting Cabotegravir + Rilpivirine for HIV Treatment: FLAIR Week 96 Results

European Meeting on HIV & Hepatitis 2020

Optimisation of First-Line Antiretroviral Therapy (ART) for Children Living with HIV in Uganda: Translation from policy to action

European Meeting on HIV & Hepatitis 2020

Dual therapy including dolutegravir plus boosted-darunavir ensures high rate of virological control and rare resistance selection at failure in heavily treatment experienced PLWH

European Meeting on HIV & Hepatitis 2020

Dual therapy with Dolutegravir plus Lamivudine in virologically suppressed patients

European Meeting on HIV & Hepatitis 2020

Real-world effectiveness of elbasvir/grazoprevir in the treatment of patients with hepatitis C virus genotype 1a infection in Norway

European Meeting on HIV & Hepatitis 2020

HIV A1 or B Do Not Differentially Impact Cabotegravir In Vitro Potency or Durability

European Meeting on HIV & Hepatitis 2020